Skip navigation
Skip navigation

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Talaulikar, Dipti; Tam, Constantine S; Joshua, Douglas; Ho, Joy Phoebe; Szer, Jeff; Quach, Hang; Spencer, Andrew; Harrison, Simon; Mollee, Peter; Roberts, Andrew W; Horvath, Noemi; Lee, Cindy; Zannettino, Andrew; Brown, Ross; Augustson, Bradley; Jaksic, Wilfrid; Gibson, John; Kalff, Anna; Johnston, Anna; Trotman, Judith; Kalro, Akash; Grigoriadis, George; Ward, Chris; Prince, H Miles

Description

Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is...[Show more]

CollectionsANU Research Publications
Date published: 2017-01
Type: Journal article
URI: http://hdl.handle.net/1885/113758
Source: Internal medicine journal
DOI: 10.1111/imj.13311

Download

File Description SizeFormat Image
01_Talaulikar_Treatment_of_patients_2017.pdf705.81 kBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  23 August 2018/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator